The STEP 1 extension trial (Wilding et al., 2022) found that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year of discontinuation. Semaglutide (Wegovy) at 2.4mg showed approximately 14.9% weight loss at 68 weeks in STEP 1, and liraglutide (Saxenda) at 3.0mg showed approximately 8.0% at 56 weeks in SCALE. These are population-level averages — in the trials, some participants lost significantly more weight than the average, while others lost less. Patients should be asked about barriers to adherence to giving a weekly injection. Important attributes driving patient preferences for particular medications include dose frequency, efficacy, adverse event profiles, and if the medication is provided as an injection, injection preparation, type of device, and needle size.90 Semaglutide is provided as a prefilled, single-dose pen with an integrated needle. Without coverage, the average wholesale price for a 30-day supply of semaglutide 2.4 mg is $1619 (USD).88 This is similar to the cost of liraglutide ($1619) but higher than most other medications including orlistat (over the counter; $41), phentermine/topiramate ER ($223), and naltrexone/bupropion ER ($364). In vitro studies have shown a low potential for semaglutide to affect CYP enzymes orinhibit drug transporters. In humans, it is unknownwhether semaglutide causes thyroid C-cell tumors, including MTC. Comparison of Efficacy, Side Effects, Contraindications, and Significant DrugInteractions for Common Antiobesity Medications. Lifestyleinterventions for all patients included counseling, a reduced-calorie diet, andincreased physical activity. GLP-1 Weight Loss Projection — Ozempic, Mounjaro & Saxenda A series of randomized controlled trials (RCTs) have consistently demonstrated the great efficacy of semaglutide for weight management 7-12. The maintenance semaglutide dose was 1 mg in 16 cases and 2 mg in nine cases, leading to a similar weight loss of 13.6% (14.9 kg) and 12.8% (14 kg), respectively. Among 25 patients with six-month data, 22 (88%), 17 (68%), and eight (32%) patients exceeded 5% (5.6 kg), 10% (11.2 kg), and 15% (16.8 kg) weight loss, respectively. Semaglutide 2.4 mg for 2 years resulted in substantial and sustained changes in body weight versus placebo in STEP 5 (−15.2% vs. −2.6%),42 demonstrating encouraging long‐term maintenance of weight loss. A slightly higher proportion of participants experienced GI AEs in the semaglutide 2.4 mg group versus the semaglutide 1.0 mg group (63.5% vs. 57.5%, respectively, and vs. 34.3% in the placebo group).39 In the STEP 6 trial, which included once‐weekly semaglutide 1.7 mg, GI AEs were reported in fewer participants in the semaglutide 2.4 mg group compared with the 1.7 mg group (59% and 64%, respectively).44 STEP 2 was the only trial to include a once‐weekly semaglutide 1.0 mg treatment arm in addition to the placebo arm. No long-term retatrutide discontinuation data exists yet, but based on tirzepatide and semaglutide evidence, significant regain is expected when the drug is stopped. TRIUMPH-4 enrolled participants with obesity plus knee osteoarthritis. The fastest loss velocity occurs in months 3–6 during active dose escalation. The average reduction in body weight with semaglutide was 15.3 kg, with weight loss of ≥5% achieved by 86% in the semaglutide group versus 31% in the placebo group. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 and 1.9 percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% and 0.1% respectively . The threshold of losing more than 5%, 10%, and 15% body weight were reached by 86.4%, 69.1%, and 50.5% participants in semaglutide group when compared to 31.5%, 12.0%, and 4.9% participants in the placebo group . STEP 8 is the first direct comparison of semaglutide with another weight‐management medication in a randomized trial. The STEP 6 results indicate that semaglutide 2.4 mg is an effective weight management option also in people from east Asia with obesity, and further illustrates a semaglutide‐induced reduction in visceral fat, which are known to be a strong predictor of weight‐related comorbidities, particularly in people from east Asia.44 Rather, the results show the effectiveness of semaglutide 2.4 mg in those with overweight or obesity, probably through its ability to control appetite, energy intake and food cravings. However, the benefit of the higher dose is seen in the context of greater weight loss.39 In terms of AEs, diabetic retinopathy events were reported in 4.0% of patients receiving semaglutide 2.4 mg, 2.7% with semaglutide 1.0 mg and 2.7% with placebo.39 Keep reading to learn more on how this treatment can support various aspects of health and vitality. To check pricing on all of our body contouring procedures, click here. And if you’d like to schedule a consultation, you can pay for the $100 consultation fee here and it will go towards the cost of the weight management program. For pricing on our weight management program, click here. So in other words, any doubts people may have about semaglutide from a compounding pharmacy should be put to rest. Contributed to the study design of some of the underlying trials, interpreted the data and wrote the manuscript. Caution should be used in interpreting the mediator analysis, which assumes that all confounding variables have been included (baseline body weight, country and stratification factor) with no additional unmeasured confounding factors. The safety findings were similar to those reported with semaglutide in the individual SUSTAIN 1 to 5 trials.15, 16, 17, 18, 19 In general, the GI disorder AE rate was higher with semaglutide than with comparators, with more GI AEs occurring in the lower versus higher baseline BMI subgroups. Adverse events by baseline BMI (pooled data from SUSTAIN 1 to 5 trials) Sustain trials reported gastrointestinal adverse effects mainly as a reason for discontinuation of the drug 22-24. And malignant neoplasms were identified in 1.7% of patients in the oral semaglutide group and 0.5% in the empagliflozin group in the Pioneer 2 trial . In addition, a weight loss response of ≥5% was seen in 52% receiving semaglutide compared to 17% of subjects receiving exenatide ER . The articles were screened based on the title and abstract related to semaglutide and obesity treatment. We included 12 randomized controlled trials (RCTs) in our study. In the STEP 2 trial, participants were excluded if they had uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Data are reported for the randomized period (i.e. weeks 20‐68). AEs, serious AEs, AEs leading to discontinuation, AEs reported in ≥10% of participants in any trial and safety focus area AEs are detailed in Table 3.38, 39, 40, 41, 42, 43 More patients receiving semaglutide decreased use of concomitant glucose‐lowering medications. For STEP 1 and 2, lipid parameters were initially analysed on a log scale as estimated ratio of end of treatment value to baseline. Figure 1. Flowchart of the Study. There was a mean percentage reduction of glycated hemoglobin (HBA1C) of − 1.9 ± 1.4%, − 1.5 ± 1.9%, and − 1.5 ± 1.7% after 6, 12 and 24 months in the IS group. 46 patients in the OS group had a mW and mBMI reduction of − 6.7 ± 5.3 kg and − 2.6 ± 2.1 kg/m2. Of these, 129 (75F, 54 M; mean age 61.2 ± 9.8 years) patients were treated with IS and 46 (24F, 22 M; mean age 65.7 ± 12.8 years) with OS for T2DM and WL. All prescribing, dosing, and treatment decisions should be made by a qualified healthcare provider based on individual medical needs. Semaglutide 2.4 mg plus lifestyle intervention provided significant, clinically relevant reductions in body weight versus placebo among adults with overweight/obesity.16 After withdrawal of semaglutide and structured lifestyle intervention, participants regained a mean of two‐thirds of their prior weight loss in the 1‐year off‐treatment extension phase; weight regain continued until the end of follow‐up (week 120).Mean body weight data suggested a slowing of weight regain towards the end of the extension phase in participants withdrawn from semaglutide.After 12 months of OS treatment HBA1C was 6.3 ± 0.7%, with a mean reduction of and − 0.8 ± 0.6% (Fig. 4).Subjects were subdivided by baseline BMI and reporting (yes/no) of any nausea and/or vomiting.Each pathway adds a layer of effect, which is why the weight loss figures sit above anything a single or dual agonist has produced.Of note, rates of discontinuation due to of AEs were lower with semaglutide than with liraglutide (3.2% vs. 12.6%).43In our cohort of 175 patients, 94 (53.7%) had weight loss of at least 5% and 26 (14.9%) had weight loss of 10% or more at 3 months. KKa contributed to the data analysis and interpretation and manuscript development. Another limitation was the potential for obesity pharmacotherapy use during the extension. The key limitations of the extension were the relatively small sample size compared with the main STEP 1 trial population and the selection of sites based on those with the highest recruitment in the STEP 1 main phase, which could introduce an element of selection bias. Has received speaking or consultancy fees from AstraZeneca, Lilly, Merck, Novo Nordisk and Sanofi; research funding for clinical trials (all paid to the institution) from AstraZeneca, Boehringer Ingelheim, Lilly, Mannkind Corporation, Medtronics, Mylan Pharmaceuticals, Novo Nordisk and Sanofi; and travel funding from AstraZeneca, Lilly, Novo Nordisk and Sanofi.Weight changes ranged between 3.6% and −14.3% at 3 months and between −0.6% and −29.1% at 6 months.The strengths of the STEP 1 extension include the pragmatic trial design, with no active intervention and infrequent site contact.Furthermore, urine albumin‐to‐creatinine ratios were improved with semaglutide in STEP 2.39When obesity pharmacotherapy users were excluded, changes in body weight (Figure 1C) were similar to the full ExAS (Figure 1A).Retatrutide weight loss results from clinical trials are unlike anything previously recorded for a pharmaceutical treatment. The data for SUSTAIN 7 were not available at the time of this analysis, and have therefore not been included.21 Overall, 15.2% to 24.0% and 21.5% to 27.2% of subjects experienced nausea or vomiting with semaglutide 0.5 and 1.0 mg, respectively, versus 6.0% to 14.1% with comparators. Subjects were subdivided by baseline BMI and reporting (yes/no) of any nausea and/or vomiting. Unlike most obesity drugs where a plateau arrives at 60–72 weeks, retatrutide's weight loss curve had not flattened at 48 weeks in Phase 2, and Phase 3 data at 68 weeks showed continued loss. Retatrutide weight loss results from clinical trials are unlike anything previously recorded for a pharmaceutical treatment. In the STEP 1 trial, most weight loss with semaglutide occurred between weeks 8 and 52, with minimal additional loss between weeks 52 and 68. Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes. Weight loss during the treatment with semaglutide at week 52 was 16.2% compared to baseline at the dose of 0.4 mg/day, versus -2.3% for placebo. Additional Benefits Beyond Weight Loss This real-world retrospective study of semaglutide therapy for weight loss in adults without DM demonstrated a significant median six-month weight loss of 13.3% (14.9 kg), with 68% (17 out of 25 individuals) achieving at least 10% weight loss, in combination with a favorable safety profile. Regarding the effectiveness of semaglutide therapy following bariatric surgery, one individual who had undergone sleeve gastrectomy in 2008 was included, with three-month and six-month weight loss of 5.5 kg (4.9%) and 8 kg (7.1%), respectively, with mild gastrointestinal side effects. Individuals on 1 mg dose experienced a median weight loss of 13.6% (14.9 kg) compared to 12.8% (14 kg) in those on 2 mg dose, with weight loss greater than 10% being achieved in 10 out of 16 participants (62.5%) on 1 mg dose versus seven out of nine (77.8%) among those on 2 mg dose, as shown in Figure 2. The 23.7% of participants who lost ≥35% of their body weight is historically unprecedented for any pharmaceutical treatment. Secondary end points were the proportion of patients achieving weight loss of 5% or more, 10% or more, 15% or more, and 20% or more after 3 and 6 months and the percentage of weight loss for patients with or without type 2 diabetes after 3 and 6 months. A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more. The rate of weight loss is generally fastest during the first 20–30 weeks and then plateaus as the body reaches a new metabolic equilibrium. The study included 175 patients (132 women 75.4%; mean SD age, 49.3 12.5 years; mean SD BMI, 41.3 9.1) in the analysis at 3 months and 102 patients at 6 months. Studies and guidance will be needed to help providers and patients select an appropriate obesity treatment medication. Thus, patients should be advised about the need for continued care for long-term weight loss. Obesity is a chronic disease and as shown in the STEP 1 extension study and STEP 4 trial, weight regain occurs with cessation of the medication. For example, in STEP 2, patients taking sulfonylureas were instructed to reduce the dose by approximately 50% at treatment start, at the researcher’s discretion.39 Patients taking medications that carry the risk of hypoglycemia should be encouraged to monitor their blood glucose regularly and be provided education about preventing, recognizing, and managing hypoglycemia. Theelimination half-life of semaglutide is approximately 1 week; therefore, semaglutidewill be present for approximately 5-7 weeks after the last dose. In our study, patients with type 2 diabetes lost less weight compared with those without type 2 diabetes. Patients without type 2 diabetes achieved higher weight loss outcomes than those with type 2 diabetes, which is also shown in our study.19 Moreover, 5 patients (2.9%) had to stop semaglutide because of the intolerability of the adverse effects, while 15 (8.6%) had to either reduce the dose or remain on the same dose to avoid exacerbation of the adverse effects. Our cohort experienced a wide range of weight loss responses to semaglutide at 3 and 6 months (eFigure 2 in the Supplement). At baseline, mean weight (mW) was 101.8 ± 24.6 kg and 95.2 ± 15.0 kg; mean body mass index (mBMI) was 36.7 ± 8.7 kg/m2 and 34.3 ± 5.3 kg/m2. One published study found that approximately two-thirds of lost weight was regained within one year of discontinuation (Rubino 2021), which is why ongoing clinical follow-up is important. At that rate, 30 lb of weight loss might take roughly 4–8 months, but this varies significantly by individual. †Participants who did not use obesity pharmacotherapies (investigator‐assessed) during the extension phase. In the FAS, the presence of prediabetes was determined by investigators on the basis of available information (e.g. medical records, concomitant medication and blood glucose variables) and in accordance with American Diabetes Association HbA1c criteria.21 In the ExAS, the presence of prediabetes was determined from HbA1c assessments, as per American Diabetes Association HbA1c criteria21; prediabetes was defined by HbA1c 5.7%‐6.4% (39‐47 mmol/mol). No participants became pregnant or had bariatric surgery during the extension. Currently, Food and Drug Administration (FDA) has approved five drugs for long-term use for obesity which includes orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, and semaglutide of which phentermine is the commonly prescribed option .Prior to semaglutide treatment, four patients had received AOMs in the past, namely, a combination of naltrexone and bupropion in three cases and liraglutide in one case.In this cohort study of 175 patients with overweight or obesity, the total body weight loss percentages achieved were 5.9% at 3 months and 10.9% at 6 months.For semaglutide-treated participants without known pre-existing diabetic retinopathy at baseline, the risk of diabetic retinopathy was low and not statistically different than placebo.80 Early worsening of pre-existing diabetic retinopathy was most evident in the initial 16 weeks, during which there was a rapid improvement in glycemic control.Preliminary data from this article were reported at the 31st European Congress on Obesity (ECO 2024) 9, 10.The STEP 1 extension trial (Wilding et al., 2022) found that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year of discontinuation.There was no significant interaction between BMI and treatment difference with other comparators.There's a healthier way to lose weight with weight-loss medication. As a GLP-1 receptor agonist, Semaglutide mimics a natural hormone in the body that regulates appetite, blood sugar levels, and digestion. She has experience in pre-clinical research as part of her research project in The Department of Toxicology at the prestigious Central Drug Research Institute (CDRI), Lucknow, India. The mean age of the included participants was 48.8 years, and they had a mean BMI of 40.9 kg/m2. However, this analysis encompassed 304 patients, of which 73% were female and 93% were of White ethnicity. Data collected was weight using calibrated scales, laboratory results for fasting blood glucose FBG, lipid panel, glycosylated hemoglobin HbA1c, blood pressure BP readings, and liver function tests LFTs. Figure 2. PRISMA flow diagram for included articles. The dashed vertical line at week 68 indicates the end of the main phase and start of the off‐treatment extension phase. Free fatty acids are not reported because of different fasting requirements in the main phase (weeks 0‐68) and the extension phase (weeks 75‐120). The ExAS and FAS had similar demographics and clinical characteristics at baseline. Most participants were female (67.0%) and White (75.8%), with a mean age of 49.0 years, weight of 105.5 kg and BMI of 37.6 kg/m2. Demographic and clinical characteristics at baseline were generally well balanced across the two arms in the ExAS (Table 1). At week 52, participants in the two groups had mean losses of 15.6% and 3.0%, respectively, revealing that semaglutide-treated participants had excellent maintenance of weight loss from weeks 52 to 104. Forty-eight weeks after randomization, participants assigned to remain on semaglutide lost an additional 7.1 kg, resulting in a net 17.4% reduction in baseline weight as measured from the start of the run-in. Participants who received IBT combined with semaglutide 2.4 mg lost 16.0% of body weight at week 68 and achieved significantly greater improvements in multiple measures of cardiometabolic risk than the placebo-treated group. At week 68, semaglutide-treated participants lost an average of 14.9% of baseline weight, compared with 2.4% for those assigned to placebo. Furthermore, no patients were excluded from the study according to the retrospective nature of the study, however not all patients treated with IS or OS have reached 6-, 12- or 24-month follow-up considered for the statistical analysis. Limitations of this study include its retrospective nature as well as the different samples of patients enrolled in the two analyzed subgroups. In obese patients, further studies should probably be conducted to verify whether the weight maintenance dosage was related to the starting BMI. For the first time, therefore, weight maintenance is more easily manageable in both overweight and obese T2DM patients. Further dose adjustments (up to 1 mg or 2 mg) are made by the prescribing provider based on individual clinical response. The FDA-approved Ozempic titration schedule begins at 0.25 mg weekly for 4 weeks, then increases to 0.5 mg. Random-effects models with inverse variance weighting were used to estimate the weighted mean differences (WMDs) and relative risks (RRs) with 95% confidence intervals (CIs). It works through a different mechanism than diet and exercise alone, making it valuable for people with hormonal or metabolic factors contributing to weight gain. Starting with a lower dose and gradually increasing it helps minimize these issues. Subgroups with greater weight losses from week 0 to week 68 tended to have numerically greater weight regains from week 68 to week 120, but maintained numerically greater net weight losses from week 0 to week 120 (Figure 1B and Table S3). ‡Participants who shifted from prediabetes at baseline to normoglycaemia at week 68 to prediabetes at week 120. From September 2019 to April 2020, 336 participants from the main phase were screened for the extension and 333 entered the extension, including 232 participants who received semaglutide during the main phase (referred to as the “semaglutide arm” hereafter) and 101 who received placebo during the main phase (“placebo arm” hereafter). Missing observations were multiply (x 1000) imputed from participants within the same randomized treatment arm with available measurements at week 68. Randomized clinical trials, adult population, human-based studies, obtainability of free full text, and articles published between 2012 and May 2022. A decrease in appetite and craving for food, a relatively low proclivity for fatty, energy‐rich foods, and better control of eating are the most likely mechanisms for semaglutide-induced weight loss . Information about data access request proposals can be found at novonordisk‐trials.com. The benefits remaining at 1 year post‐withdrawal appear to be related to the magnitude of initial weight loss at week 68. Reversion from normoglycaemia to prediabetes after semaglutide withdrawal may relate to loss of the direct effects of GLP‐1 receptor agonism on glycaemic levels. In this real-life study, the rate of gastrointestinal side effects was 55%, mostly mild to moderate with only 7.5% of individuals experiencing serious adverse events, compared to a 74%-84% rate for gastrointestinal side effects and 7.9%-9.8% for serious side effects in STEP trials 7,9,10. It remains unclear to what extent weight loss, the improvement of metabolic risk factors, and possible pleiotropic anti-atheroslcerotic effects contribute to the semaglutide-related reduction of cardiovascular risk . The efficacy of semaglutide in patients with active psychiatric diseases is not known since all individuals with major depressive disorders or other severe psychiatric disorders within the last two years were excluded from STEP trials . Our observation provides evidence in favor of gender-specific differences in semaglutide-related outcomes, as already suggested by a subgroup analysis of STEP trials recording a greater mean weight reduction in females of 14%-16.2% compared to 8%-9.3% in males . The role of the chronic use of lower maintenance semaglutide doses in clinical practice, especially in individuals with great initial response or persistent gastrointestinal side effects, remains unclear and needs to be explored further. The extension was offered in five selected countries (Canada, Germany, Japan, the UK and the United States) that were representative of the global trial population and aimed to include approximately 300 participants.Mean values of fasting glucose, hemoglobin A1c, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides at baseline are presented in Table 1.In the case of exenatide ER, it may be related to its exendin‐4‐derived structure, which has a much lower amino acid sequence homology to native human GLP‐1 than semaglutide.Only a healthcare professional can determine whether Wegovy® (semaglutide) is the appropriate option for you.Average baseline weight was 109 kg (240 lbs), average BMI was 38.8, roughly 52% were men.If participants were unable to tolerate the 2.4 mg dose because of adverse events (AEs), lower maintenance doses were permitted if the participant would otherwise discontinue trial treatment completely.The subgroup analysis for the gender and BMI category was conducted in order to examine the impact of baseline characteristics on the magnitude of semaglutide-induced weight loss. Sustain 6 trial conducted by Marso et al. at 230 sites in 20 countries assigned 3297 patients with type 2 diabetes who were on a standard-care regimen to receive once-weekly subcutaneous semaglutide (0.5 mg or 1.0 mg) or placebo for 104 weeks . From baseline to week 26, the estimated mean body weight changes were -1.4, -2.4, -3.7, and -0.4 kg for oral semaglutide 3, 7, and 14 mg and placebo, respectively . In a similar study, Pioneer 6 conducted by Husain et al. to study the cardiovascular safety of oral semaglutide 14 mg showed there was -4.2 kg change in body weight from baseline in semagltuide group vs -0.8 kg in the placebo group . In conclusion, among adults with overweight/obesity, after a substantial reduction in body weight during 68 weeks of treatment with once‐weekly s.c. Obesity is a major health problem worldwide resulting in numerous health conditions such as heart disease, stroke, type 2 diabetes (T2D), and certain types of cancer which are among the leading causes of premature preventable deaths. Individual participant data will be shared in data sets in a de‐identified and anonymized format. TKO contributed to the data analysis and interpretation and manuscript development. KKo contributed to the data analysis and interpretation and manuscript development. An important finding of STEP 2 was that individuals with type 2 diabetes can expect to lose approximately one-third less weight than those without this condition. Changes in these values were generally similar in the two semaglutide-treated groups, although the data were not submitted to formal statistical analysis. Marked variability in the therapeutic result of semaglutide highlights the need to identify the predictors of response and assess the efficacy of lower semaglutide doses, facilitating personalized decision-making. Fifth, the homogenous ethnic background with all the participants being white Greek, the preponderance of females, and the bias regarding the socioeconomic status because of patients self-funding the cost of medication limit the generalizability of these findings to broader populations. In the future, the availability of numerous potent AOMs could usher in an era of precision medicine with the application of personalized treatment strategies, based on predictive models, encompassing age, gender, different obesity phenotypes, coexisting complications, genotype, and predictors of response to each treatment modality . Two published trials directly compare semaglutide to liraglutide; another GLP-1receptor agonist indicated for weight loss. Considering the observational nature of this study, we could not compare weight loss outcomes between patients receiving semaglutide and controls. In addition, the weight loss data of semaglutide use might be more representative of day-to-day clinical practice, including a more heterogenous patient population, compared with RCTs. In a multicenter clinical experience assessing the outcome of FDA-approved AOMs (eg, phentermine-topiramate, liraglutide, orlistat, and naltrexone-bupropion), weight loss of 5.0% was achieved at 3 months compared with 5.9% in the present study, and weight loss of 6.8% was achieved at 6 months compared with 10.9% in the present study. Among participants with type 2 diabetes in the STEP 2 trial, the reduction in body weight with semaglutide 2.4 mg was 9.6% (vs. 7.0% for semaglutide 1.0 mg and 3.4% for placebo) from baseline to week 68 (Table 2). Across the phase 3 trial program for type 2 diabetes (SUSTAIN),semaglutide consistently demonstrated clinically significant weight loss (up to -6.5kg with 1.0 mg semaglutide).6-12 Subsequently, semaglutide hasbeen approved at a higher dose, 2.4 mg, as an adjunct to a reduced-calorie diet andincreased physical activity for chronic weight management in patients who haveobesity, or are overweight with at least one other weight-related comorbid condition.13 This article reviews clinical trials assessing the efficacy and safety ofsemaglutide at a dose of 2.4 mg for chronic weight management. This cohort study assesses weight loss outcomes of semaglutide at doses used in randomized clinical trials for patients with overweight or obesity. Individuals randomized to continue semaglutide lost an additional 7.9% in body weight from weeks 20 to 68, whereas individuals who switched to placebo experienced a mean 6.9% increase.41 In STEP 8, mean weight loss was greater with semaglutide 2.4 mg than with liraglutide 3.0 mg from baseline to week 68 (15.8% vs. 6.4%).43 However, when compared toaverage weight loss seen in major clinical trials of other FDA-approved medications,semaglutide 2.4 mg consistently showed greater weight loss and a greater proportionof patients achieving 5% body weight loss in STEP program trials.5,43 Additionally, semaglutide 2.4mg has fewer restrictions on its use than most other FDA-approved medications,excluding orlistat and liraglutide 3 mg. This subset comprised all eligible participants from any site in Canada, Germany and the UK, and sites in the United States and Japan with the highest main phase recruitment. Furthermore, the safety profile of semaglutide 2.4 mg was as expected for the GLP‐1RA class. For more persistent or severe GI symptoms, pausing of dose escalation is recommended, and short‐term use of over‐the‐counter medications may be considered. Provide your current weight and height to see projected weight loss with each GLP-1 medication based on published clinical trial data. Recently, in a fundamental study on obese population with pre-existing cardiovascular diseases (Select study) semaglutide determined a weight loss up to approximately the 65th week and this result on weight loss was maintained after 4 years from the beginning of the therapy with semaglutide . To provide a comparison on efficacy, patients on liraglutide 3.0 mg, at week 52, had similar weight loss as those on 0.2 mg of semaglutide . Tirzepatide has shown promising results on obesity with a side effect profile close to semaglutide. Semaglutide regulates blood glucose via the incretin pathway, stimulating insulin and inhibiting glucagon secretion in a glucose‐dependent manner, leading to lower blood glucose levels with low risk for hypoglycaemia.68 In STEP 2, insulin treatment was only allowed for rescue therapy and those taking sulphonylureas were to reduce the dose by 50% to reduce the risk of hypoglycaemia. For mild and short‐term GI side effects, this should include providing advice on dietary modifications and recommending that patients increase their fibre and water intake for constipation and consider stool softeners. In December 2025, Eli Lilly released top-line results from TRIUMPH-4, the first Phase 3 retatrutide trial to report outcomes. Retatrutide simultaneously activates three receptor pathways — GLP-1, GIP, and glucagon — producing additive metabolic effects no single or dual agonist achieves alone. Access is currently limited to trial enrolment and compounding pharmacies. This injectable drug works by mimicking the effects of the GLP-1 gastrointestinal hormone, which regulates appetite and promotes a feeling of fullness. There's a healthier way to lose weight with weight-loss medication. Whether you’re just starting or taking the maximum dose or anything in between, this video will guide you through the proper way to inject So patients are resorting to compounded versions of the active ingredients Effectiveness assessment of weight loss and weight loss maintenance after IS and/or OS As previously reported in the individual SUSTAIN 1 to 5 trials,15, 16, 17, 18, 19 a significantly greater proportion of semaglutide‐treated subjects achieved ≥5% and ≥10% weight loss versus comparators (Figure S1, Supporting Information). In general, greater absolute weight loss in kg was observed in subjects with higher baseline BMI for both semaglutide doses as well as for comparators, with the exception of insulin glargine in SUSTAIN 4. The model used to impute counterfactual values of body weight also included the interaction between treatment and each baseline variable and the interaction between any nausea or vomiting and each baseline variable. Furthermore, patients with obesity experienced significant improvements in metabolic, lipid profile, blood pressure, liver function tests, and CVD outcomes. At 12 months, patients without T2DM achieved a higher TBWL than patients without T2DM (16.9 vs. 9.9). The prescribed doses of semaglutide were 0.25, 0.5, 1, 1.7, 2, or 2.4 mg. Specifically, they assessed whether its use was safe and improved weight loss, metabolic, and comorbidity outcomes, including 10-year atherosclerotic cardiovascular disease ASCVD risk. All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. In SUSTAIN 1 to 5, semaglutide‐induced weight loss was consistently greater versus comparators, regardless of baseline BMI. Semaglutide demonstrated superior reductions in HbA1c and superior weight loss (by 2.3‐6.3 kg) versus different comparators across the SUSTAIN 1 to 5 trials; the contributing factors to weight loss are not established. The ACHIEVE Phase 3 global clinical development program for orforglipron has enrolled more than 6,000 people with type 2 diabetes across five global registration trials. In the case of exenatide ER, it may be related to its exendin‐4‐derived structure, which has a much lower amino acid sequence homology to native human GLP‐1 than semaglutide. Overall, nausea and vomiting events were mostly transient, with a median duration of between 1 and 8 days with the semaglutide 0.5 and 1.0 mg and comparator groups. These results were broadly similar to the overall population and to those with a baseline BMI 2, with the exception of SUSTAIN 3 (10% threshold) and SUSTAIN 5 (5% and 10% thresholds), in which proportionately fewer subjects achieved these targets than in those with low baseline BMI (Figure S1, Supporting Information). This effect was more marked with semaglutide 1.0 mg than with 0.5 mg. STEP 4 investigated the impact of continued semaglutide 2.4 mg treatment, vs switching to placebo, on maintenance of weight loss in participants who reached 2.4 mg of semaglutide during a run-in period. Subcutaneous (s.c.) semaglutide, a glucagon-like peptide-1 analogue, has shown clinically-relevant weight loss in a phase 2 trial in people with obesity. Based on the results of our weight management program, our patients have lost an average of 7.7 pounds in only 4 weeks on the lowest, introductory dose of semaglutide! Additionally, ongoing, and future GLP-1 analog studies that include longer follow-up, more diverse study populations, evaluations of the weight loss effects of oral semaglutide formulations, and assessments of cardiovascular outcomes data are needed. In summary, this important study shows that once weekly 2.4 mg dosing of semaglutide provides safe, well-tolerated and substantial weight loss in individuals with overweight or obesity, as well as an improvement in cardiometabolic risk factors and physical function measures. Despite the wealth of high-quality evidence, there is a paucity of real-life data limited to one cohort study . These promising results suggest that a variety of novel pharmacotherapies will become available in the next few years, revolutionizing the treatment of obesity . This indication followed its initial approval for the treatment of type 2 diabetes mellitus (DM) in 2017. Despite this unmet clinical need, anti-obesity medications (AOMs) have been underutilized in routine clinical practice, with less than 1.5% of those eligible for pharmacotherapy having received AOMs . Weight Loss Timeline — All Medications That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.In the STEP 2 trial comparing 1 mg and 2.4 mg of semaglutide for patients with type 2 diabetes, similar weight loss trends compared with those in our study were seen.This study is one of the few head-to-head comparisons of individual therapies for weight management and demonstrated the superiority of semaglutide, relative to liraglutide, in weight loss.The contribution of nausea or vomiting to this weight loss was minor.The first two visits of the off‐treatment observational extension phase coincided with the week 68 and week 75 visits in the main phase, with three further visits conducted at weeks 80, 104 and 120 (Figure S1).Research consistently shows that weight regain occurs after discontinuing GLP-1 medications.This GLP-1 Weight Loss Projection Calculator is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Mean values of fasting glucose, hemoglobin A1c, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides at baseline are presented in Table 1. For secondary end points, categorical data were analyzed using the Fisher exact test, and the 2-sample independent t test was used for continuous data. During data abstraction, we confirmed the medication start date from physicians’ EMR notes or physician-patient communications because there might be a delay between the day of prescription and the start of medication (eg, insurance approval delay and drug availability). We also collected information on visits with dietitians and behavioral bariatric psychologists after the first day of starting semaglutide until the last day of follow-up or until the medication was discontinued. There were 408 prescriptions of subcutaneous injections of semaglutide between January 1, 2021, and March 15, 2022, at the Mayo Clinic Health System. These effects typically decrease over time as your body adjusts to the medication. Semaglutide has shown superior efficacy compared to many other weight loss medications. Research indicates that some weight regain is common when treatment stops. At Sanctuary Medical Aesthetic Center, our team of board-certified specialists provides personalized semaglutide treatment plans tailored to your specific needs and goals. The primary endpoint was percentage change in body weight between randomization (week 20) and week 68. Keep in mind that every 28 days, our patients get the next higher dose of semaglutide in 4 prefilled syringes for their once-per-week injection. Notably, the 2.4 mg weekly injection of semaglutide has recently been approved by the US Food and Drug Administration (FDA) as of June 2021 (brand name Wegovy) for the chronic management of weight in adults with obesity or overweight and at least one weight-related comorbidity,26 providing a powerful new tool in the arsenal of obesity therapies. Third, although the main side effects of semaglutide (gastrointestinal disorders) were higher than with glucose-lowering doses of semaglutide, side effects were transient, typically mild-to-moderate in severity, and mostly resolved without the need for treatment discontinuation (4.5% discontinuation for gastrointestinal symptoms in the semaglutide group). After dose escalation, many patients lose approximately 1–2 lb per week on average. Research supports approximately 1.6–2.2 g/kg of body weight for individuals in a caloric deficit (Helms 2014). A1C improvements in patients with type 2 diabetes are also commonly observed in early treatment (Marso 2016). The following table summarizes observations from clinical trial data and published real-world studies—not a recommended protocol. Ozempic (semaglutide) is an FDA-approved once-weekly injectable GLP-1 receptor agonist indicated for type 2 diabetes. As medications may have been used off‐label for weight management, obesity pharmacotherapy use was also assessed using investigator‐reported medication classification. An additional 22 participants completed the end‐of‐trial visit via telephone or email contact. Week 68 responses were examined using an analysis of covariance model with randomized treatment as factor and baseline endpoint value as covariate. Endpoints addressing the second exploratory objective were analysed descriptively and statistically using data from the in‐trial period for the ExAS. Across the STEP trials, once‐weekly subcutaneous semaglutide 2.4 mg demonstrated mean weight loss of 14.9%‐17.4% at 68 weeks in participants without diabetes with the mean baseline weight of 100‐107 kg,38, 40, 41, 43 offering the potential for clinically relevant improvement for individuals with obesity‐related diseases. Semaglutide 2.4 mg plus lifestyle intervention provided significant, clinically relevant reductions in body weight versus placebo among adults with overweight/obesity.16 After withdrawal of semaglutide and structured lifestyle intervention, participants regained a mean of two‐thirds of their prior weight loss in the 1‐year off‐treatment extension phase; weight regain continued until the end of follow‐up (week 120). Blundell et al. conducted randomized, double‐blind, placebo‐controlled, two‐period crossover trials, in 30 subjects with obesity to study the effects of 12 weeks of treatment with the therapy of once‐weekly subcutaneous semaglutide . Most patients begin to notice weight loss within the first 4–8 weeks of treatment, though the initial weeks often involve dose titration (gradually increasing the dose) to minimize side effects. Clinical trials show that weight loss with semaglutide continues beyond the initial weeks as doses are adjusted by the prescribing provider. A real-world retrospective study of 175 patients reported average weight loss of 5.9% at 3 months (Ghusn 2022), suggesting that measurable changes are typically underway during the first 6 weeks of treatment. This article summarizes what published clinical data shows about early weight changes in patients prescribed semaglutide, and what the research says about the first six weeks of treatment. Nutrition and Exercise Considerations During GLP-1 Treatment When obesity pharmacotherapy users were excluded, changes in body weight (Figure 1C) were similar to the full ExAS (Figure 1A). Changes in body weight from week 0 to week 68 and from week 68 to week 120 for these subgroups are reported in Table S4. Changes in BMI during the main treatment phase and extension phase were consistent with changes in body weight and are reported in Tables 2, S1 and S2. In the FAS, baseline lipid levels were reported for 1281‐1301 participants per variable in the semaglutide group and 645‐649 participants per variable in the placebo group. In the ExAS, baseline lipid levels were reported for 222‐227 participants per variable in the semaglutide group and 97‐98 participants per variable in the placebo group. Studies in a non-English language, animal/preclinical studies, review articles, and non-full-text articles were excluded. For other databases, keywords were used to get the relevant articles. The Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) 2020 Guidelines 14-15 are standard for systematic reviews and were used to conduct and record the data presented in this systematic review. Lifestyle interventions and dietary modifications are the initial approaches to weight reduction . This real-world study showed an early improvement in glycemic markers, confirming the glucose-lowering effect reported in STEP studies 7-9.Endpoints addressing the second exploratory objective were analysed descriptively and statistically using data from the in‐trial period for the ExAS.Right now, my weight is my number one priority.In conclusion, among adults with overweight/obesity, after a substantial reduction in body weight during 68 weeks of treatment with once‐weekly s.c.Thus, the 2.4 mg dose significantly increased weight loss, compared to 1.0 mg, the latter which was originally approved for the treatment of type 2 diabetes.The main strength of this observational study is that it is the first real-life study evaluating the effectiveness and safety of semaglutide for weight management in Europe. Participants treated with subcutaneous semaglutide 2.4 mg were initiated on a dose of 0.25 mg once weekly and the dose was escalated every 4 weeks to 0.5 mg, 1.0 mg and 1.7 mg, until the target dose of 2.4 mg was reached at week 16. Participants were randomized to receive once‐weekly subcutaneous semaglutide 2.4 mg or matching placebo for 104 weeks. STEP 441 was a 68‐week withdrawal trial, designed to assess the effect on weight change of continuing versus discontinuing once‐weekly subcutaneous semaglutide 2.4 mg after an initial 20‐week semaglutide run‐in period. These weight loss outcomes are comparable with a three-month percentage weight loss of 6%-6.5% and six-month of 10.6%-12% reported in STEP 1 and STEP 4 trials 7,8, suggesting that semaglutide achieves a similar effect in routine clinical practice with that observed in RCTs. In almost two-thirds of the participants, substantial weight loss was produced despite being treated with 1 mg weekly, lower than the maintenance-licensed semaglutide dose of 2.4 mg weekly. After three months of semaglutide administration, the median weight reduction was 7.4 kg (6.6% of the baseline weight), with 28 (70%) and eight patients (20%) achieving greater than 5% (5.6 kg) and 10% (11.2 kg) weight loss, respectively. In the tirzepatide withdrawal trial, participants who stopped after achieving ~21% weight loss regained approximately 14% of their original body weight within one year. I definitely gained a significant amount of weight during my first few years in college. Now, I'm doing something to lose weight. I started taking Wegovy® a little over two years ago to help me lose weight and keep it off. Can determine whether Wegovy® (semaglutide) is the appropriate Only a healthcare professional can determine whether Wegovy® (semaglutide) is the appropriate option for you. Compared with baseline, at week 120, observed mean HbA1c was reduced in the semaglutide arm and similar in the placebo arm (Figure 2, Table 2). During treatment, a greater decrease in HbA1c was observed from week 0 to week 68 with semaglutide than placebo (Tables 2 and S1), which was slightly larger in the ExAS than in the FAS (Table S2). Improvements were observed in some cardiovascular risk factors from baseline to week 120 (Figures 2 and S3 and Table 2), including for LDL cholesterol and CRP in both semaglutide and placebo arms and for HDL cholesterol, VLDL cholesterol and triglycerides in the semaglutide arm. During treatment, greater improvements in cardiovascular risk factors were observed from week 0 to week 68 with semaglutide than placebo (Tables 2 and S1), which tended to be slightly larger in the ExAS than in the FAS (Table S2). Caution should be taken when using semaglutide in patients with diabetic retinopathy, and retinal screenings should be performed regularly to detect progression of retinopathy. The risk of hypoglycemia is low overall but increases when semaglutide is combined with diabetes medications known to cause hypoglycemia such as sulfonylureas, meglitinides and/or insulin therapy. The increase in heart rate with semaglutide is especially important to consider for patients with heart failure and other cardiac conditions, and the safety of semaglutide in this population is unclear. No increase in QT intervals or adverse cardiac events have been noted.30,76 Heart rate should be monitored in participants taking semaglutide. There is limited evidence from trials and real‐world studies on strategies for managing GI side effects of GLP‐1RA treatment. Semaglutide should be initiated at a dose of 0.25 mg once weekly and then escalated every 4 weeks according to the dose‐escalation schedule in Figure 1, until the maintenance dose of 2.4 mg once weekly is reached.20, 21 This escalation schedule is designed to minimize GI AEs, but if a patient does not tolerate a dose during the escalation period, the subsequent escalation step can be delayed for a further 4 weeks, after which it should be re‐escalated to 2.4 mg. The encouraging data from validated patient‐reported outcomes (Short Form‐36 Version 2 Health Survey, Acute Version in STEP 1‐4 and Impact of Weight on Quality of Life‐Lite Clinical Trials Version questionnaire in STEP 1 and 2) point towards the benefits of semaglutide 2.4 mg being directly perceived by study participants. Earlier data from PIONEER 6 and SUSTAIN 6 suggested a CV benefit of semaglutide at lower doses in individuals with type 2 diabetes.61 Together, these findings indicate a potential role for semaglutide in the management of cardiometabolic risk factors. Additional strengths include the multinational setting and the high rates of trial completion. The strengths of the STEP 1 extension include the pragmatic trial design, with no active intervention and infrequent site contact. A longer follow‐up study is needed to determine if these remaining benefits would ultimately be lost or retained. However, the differences in weight loss between baseline BMI subgroups were comparatively small, and a meaningful effect of baseline BMI cannot be concluded based on the present data. Despite the small difference between men and women, weight losses during treatment were still substantial and clinically meaningful in both sexes. Furthermore, the absence of structured lifestyle intervention following semaglutide withdrawal contrasts with the continuation of lifestyle intervention in other withdrawal trials (including in STEP 4)13, 14, 15 and may also have contributed to the trajectory of weight regain. Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health. Cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted towards baseline at week 120 for most variables. Among new molecules on the horizon for the treatment of overweight and obesity, the most promising appears to be tirzepatide (LY ), an incretin mimetic with a dual action targeting both the GLP‐1 receptor and the glucose‐dependent insulinotropic polypeptide (GIP) receptor75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 (Figure 2 and Supplementary Figure 1). Ongoing trials with semaglutide, and selected ongoing and completed trials with other investigational agents. You also might experience some mild side effects like nausea, but those will likely pass in coming days, she says. They mimic a hormone you already produce in your body that signals fullness, says Rekha Kumar, MD, an endocrinologist at NewYork-Presbyterian and Weill Cornell Medicine. People can lose on average anywhere from five to 20 percent of their weight on these drugs in one year, depending on their starting point, research has found. Remember that this is the average weight loss. From a health policy standpoint, despite the major clinical and public health impact of obesity, there is currently poor insurance coverage for obesity pharmacotherapies in the US. This is key, as the majority of anti-obesity medications currently approved for use in the US are only indicated for short-term use because of significant side-effects and safety considerations.20 With the prevalence of obesity and related-cardiovascular complications on the rise, there is clear need for additional effective, non-surgical strategies for treating overweight and obesity. Your genetics will also impact how effective and how responsive you are to semaglutide, and this is true for all medications, says Dr. Kumar. A higher dose doesn’t always mean better results. The dosage doesn't necessarily influence when the onset of side effects will occur—but mainly, their severity. After 60, your metabolism starts to decline by less than one percent per year, according to a 2021 study published in Science. For many women, this can start in their 40s, and weight gain often continues at about the rate of 1.5 pounds each year throughout their 50s, per Mayo Clinic. The total response rate was 72.5% (29 out of 40 individuals), using a cutoff of achieving a minimum 5% weight reduction within a three-month period to define clinically relevant weight loss. Out of 40 patients, 28 (70%) and eight (20%) patients achieved greater than 5% (5.6 kg) and 10% (11.2 kg) weight loss, respectively, as illustrated in Figure 1. Among the 40 individuals, the median weight was 111.7 kg, and BMI was 39.7 kg/m2, with half of the patients having class III obesity. Prior to semaglutide treatment, four patients had received AOMs in the past, namely, a combination of naltrexone and bupropion in three cases and liraglutide in one case. Semaglutide for weight management was prescribed for a total of 43 patients who were overweight or obese, but the analysis included 40 individuals (28 females and 12 males) following the exclusion of three individuals owing to the lack of three-month data. Over a year or more, this can translate to a total weight loss of up to 15 percent. Semaglutide plays a pivotal role in regulating appetite and boosting metabolism, which are key factors in achieving significant weight loss. By addressing these key pathways, Semaglutide not only promotes weight loss but also enhances overall metabolic health, reducing the risk of weight-related complications. This dual-action mechanism makes it highly effective in promoting sustainable weight loss when combined with a balanced diet, regular exercise, and consistent medication use. Future research efforts should not only evaluate the potential synergistic effect of combining semaglutide with other AOMs and different lifestyle interventions but also explore its use as neoadjuvant or adjuvant therapy along with bariatric surgery. Moreover, the lack of a strictly controlled lifestyle intervention in combination with possible differences in individual adherence introduces a potential confounder, since varying responses may be explained by different types and intensities of lifestyle modification in subgroups, rather than different drug effects per se. In view of the substantial budgetary effects, negotiating the price of new-generation AOMs may be needed to address health inequities across different categories of socioeconomic status, as well as ensure their affordability and equitable patient access. Proportion of subjects achieving ≥5% (A) and ≥10% (B) weight loss by baseline BMI. Only a small component (0.07 to 0.5 kg) of the total treatment difference in weight loss was explained by nausea or vomiting. Semaglutide 0.5 and 1.0 mg consistently demonstrated greater weight loss, regardless of baseline BMI, versus all comparators. In summary, across the SUSTAIN 1 to 5 trials, once‐weekly s.c. The use of post‐baseline values (GI AEs in this case) in the analyses complicates the otherwise simple causal inference from a randomized controlled clinical trial. The model used to impute counterfactual values of body weight also included the interaction between treatment and each baseline variable and the interaction between any nausea or vomiting and each baseline variable.The cost-effectiveness of semaglutide is unclear, though one recent study demonstrated that semaglutide, relative to no treatment, diet and exercise alone, and other anti-obesity medications, was cost-effective at the willingness-to-pay threshold of $150,000 per quality-adjusted life year over a 30-year horizon.89 As part of the shared decision-making process, insurance coverage and out-of-pocket expenses should be discussed openly with patients.BMM contributed to the conduct of the trial, data collection, analysis and interpretation and manuscript development.The Mayo Clinic Diet now supports your journey with a special Companion program for weight-loss medication.Anti-obesity medications, when combined with lifestyle intervention, produce larger weight losses than behavioral treatment alone.17 Guidelines and expert opinions for adult obesity treatment specify that candidates for anti-obesity medications are individuals with a body mass index (BMI) ≥30 kg/m2, or a BMI ≥27 and 2 with at least one weight-related condition (such as hypertension, dyslipidemia, or type 2 diabetes), who have not met weight-loss goals with ILI.If you get a lump or swelling in your neck or an allergic reaction, serious side effects may happen, including pancreatitis.Further studies will be necessary to understand what the dosage will be to maintain weight.In Step 1 trial, one gallbladder-related adverse event mostly cholelithiasis was reported .In this real-life study, the rate of gastrointestinal side effects was 55%, mostly mild to moderate with only 7.5% of individuals experiencing serious adverse events, compared to a 74%-84% rate for gastrointestinal side effects and 7.9%-9.8% for serious side effects in STEP trials 7,9,10. Consistent weekly injection timing matters more for drugs with half-lives near the dosing interval. Retatrutide has a half-life of approximately 6 days, close to the weekly dosing interval. Titrating deliberately rather than aggressively often allows higher final doses with better tolerability. If you experience significant GI side effects that force you to slow or reverse titration, your overall result will land lower. The dose-response relationship in retatrutide is steep and consistent. Collected data as an investigator in some of the underlying trials, interpreted the data and wrote the manuscript. Has received consultancy fees (all paid into University funds) from GW Pharma, Janssen, Lilly, Merck, Novo Nordisk, Orexigen and Takeda; research grants for clinical trials from Janssen, Novo Nordisk, Sanofi and Takeda; and travel grants for conference attendance from Janssen and Novo Nordisk. Has received speaking or consultancy fees from AstraZeneca, Lilly, Merck, Novo Nordisk and Sanofi; research funding for clinical trials (all paid to the institution) from AstraZeneca, Boehringer Ingelheim, Lilly, Mannkind Corporation, Medtronics, Mylan Pharmaceuticals, Novo Nordisk and Sanofi; and travel funding from AstraZeneca, Lilly, Novo Nordisk and Sanofi. We thank all the participants, investigators and trial‐site staff who were involved in conducting the SUSTAIN 1 to 5 trials. The United States Food and Drug Administration (FDA) has approved five medications, as adjuncts to a reduced-calorie diet and increased physical activity, for chronic weight management. These include its efficacy and safety, as well as its contraindications, potential adverse effects, management of comorbidities and drug interactions, insurance coverage and cost, and patient preferences. In this paper, we discuss considerations for the selection of individuals who are candidates for semaglutide and special considerations related to the use of this medication. Despite these average benefits, prescribers should carefully assess the suitability of patients for this medication. In view of the potential widespread use of semaglutide, cost-effectiveness studies are of paramount importance, as well as head-to-head studies with other AOMs. Clinical trials required all participants to follow a reduced-calorie diet and increase physical activity. The SURMOUNT-1 trial (Jastreboff et al., 2022) enrolled 2,539 adults with obesity or overweight. The STEP 1 trial (Wilding et al., 2021) enrolled 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Some studies also revealed a dose-dependent effect of the therapy in those with poorly controlled diabetes. There was a confirmed case of metastatic pancreatic cancer with an onset date of 65 days after the end of treatment in Sustain 5 Trial, in addition to one more case in Sustain 6 trial 23-24. The mean pulse rate increased significantly with oral semaglutide 14 mg but not with 3 or 7 mg in Pioneer 1 Trial as well as 2-4 beats increase in pulse rate in the pioneer 8 trial 13, 20. In Pioneer trials, nausea of mild to moderate intensity was noted which was the main reason for premature discontinuation 13, 19-21. Step 1 trial extension conducted by Wilding et al. included 327 participants. All participants received weekly subcutaneous injections of retatrutide at 9mg or 12mg, or placebo, for 68 weeks. Of the 102 patients who were followed up at 6 months, 89 (87.3%) achieved weight loss of 5% or more, 56 (54.9%) achieved weight loss of 10% or more, 24 (23.5%) achieved weight loss of 15% or more, and 8 (7.8%) achieved weight loss of 20% or more. Projections reflect mean weight loss reported in published peer-reviewed trials. The benefits of sustained weight loss (reduced risk of type 2 diabetes, cardiovascular disease, sleep apnea, and certain cancers) generally outweigh the risks for most eligible patients. Percentage changes in glycated hemoglobin (HBA1C) were also calculated from baseline in both subject groups of treatment. OS therapy was administered once daily at the starting dose of 3 mg and with monthly increases up to 14 mg in all patients. IS treatment was administered once weekly subcutaneously. Oral Semaglutide 50 mg also induced a significant WL compared to placebo (15.1% versus 2.4%) , however the use in clinical practice of oral Semaglutide 50 mg is not yet approved. GLP1-RA have demonstrated effectiveness in lowering glycated hemoglobin (HbA1C), decreasing weight, and reducing the risk of major cardiovascular events in patients with T2DM. Common side effects, contraindications,drug interactions, and clinical pearls for these medications are shown in Table 2.5,13,24-35 Gastrointestinal side effectsof semaglutide 2.4 mg may limit its usability in some patients. Whilethis was not directly evaluated in the STEP program, trials have demonstratedimproved adherence with once-weekly GLP-1 therapy for diabetes mellitus overonce-daily therapy.41,42 In a phase 2 trial, daily doses ofsemaglutide (0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg) were compared toliraglutide 3.0 mg daily or placebo. Five of these trials have been published.16-21 The results of STEP 5 werepresented at the 2021 Annual Meeting of the Obesity Society but have not beenpublished at the time of manuscript writing.20 Additionally, cardiovascular benefits of semaglutide 2.4 mg are beingevaluated in the SELECT trial, which is currently enrolling patients.22 Details of these trials are shown in Table 1. If patients do not tolerate the maintenance dose,the dose may be decreased to 1.7 mg for 4 weeks followed by escalation back tomaintenance dosing. One night I was talking with my neighbor about my weight. My doctor started expressing concerns about my excess weight and its impact on things like my blood pressure. When I was carrying all that weight, I was getting winded going up a flight of stairs. I was playing basketball four to five times a week. When added to basal insulin, subcutaneous semaglutide in patients with uncontrolled T2DM it remarkably reduced HbA1c and body weight when compared to placebo in Sustain 5 Trial, a double-blinded RCT . Pioneer 1 Trial, an RCT conducted by Aroda et al. to compare the efficacy and safety of oral semaglutide to placebo in patients with type 2 diabetes which included 703 patients for 26 weeks who were randomized to receive 3, 7, or 14 mg oral semaglutide or placebo . Weight losses with semaglutide versus placebo from week 0 to week 68 were slightly greater in the ExAS than in the FAS, as expected given that the ExAS only included participants who completed 68 weeks of treatment. Although many participants who reverted from prediabetes to normoglycaemia during semaglutide treatment subsequently returned to prediabetes after withdrawal, the semaglutide arm maintained a relative improvement at week 120 compared with the placebo arm. The review found that semaglutide is safe and effective in treating obesity, and complications reported were primarily gastrointestinal events. Our systematic review aims to analyze the efficacy of semaglutide, a GLP-1RA in treating obesity. The authors thank the participants, investigators and site staff who were involved in the STEP 1 trial. RFK contributed to the conduct of the trial, data collection, analysis and interpretation and manuscript development. There was no significant interaction between BMI and treatment difference with other comparators. Differences in diabetes duration were observed, which reflected the stage the subjects were at in the continuum of type 2 diabetes care. Written informed consent was obtained from all subjects before trial commencement. Semaglutide‐treated subjects followed a fixed‐dose escalation regimen to improve GI tolerability. Outcomes vary with dose, adherence, and individual response. Discuss weight-loss expectations with your prescribing provider. More serious but less common adverse events include pancreatitis, gallbladder problems, and potential thyroid effects (boxed warning). The American College of Sports Medicine recommends resistance training at least twice per week for all adults. These are general evidence-based considerations—not treatment recommendations. The material on this website is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment. The Mayo Clinic Diet now supports your journey with a special Companion program for weight-loss medication. The program is designed for individuals who are taking weight-loss medications and would like support in developing sustainable healthy habits for long-term weight management. If you have any concerns or questions regarding semaglutide or its administration seek professional advice. Keep track of where you give each injection to make sure you rotate body areas. Considering the scarcity of AOMs, choosing the most suitable and individualized therapy is important.6 Retrospective studies comparing high doses of semaglutide (ie, 1.7 and 2.4 mg) with other AOMs are limited. Mild adverse effects did not affect dose escalation; moderate adverse effects prevented dose escalation; and severe adverse effects resulted in medication termination. Detailed information of the maximum dose reached by our cohort of patients is presented in eTable 2 in the Supplement. Of the 28 patients with type 2 diabetes, 11 (39.3%) were using a combination of insulin with metformin, empagliflozin, and/or glipizide. In our cohort of 175 patients, 89 patients (50.9%) had class 3 obesity (BMI, ≥40). Semaglutide has proven effective for many patients who struggled with other weight loss approaches. Book your consultation today and take the first step toward your weight loss goals. Located in Boca Raton and Fort Lauderdale, our expert medical professionals will guide you through every step of your weight loss journey. During this period, the combined effects of weight loss, improved metabolic health and established healthy habits often create momentum that helps maintain long-term success. Changes in body weight in the subgroup of participants who shifted from prediabetes at baseline to normoglycaemia at week 68 and then reverted to prediabetes by week 120 are shown in Figure 1D and Table S4. Participants in the semaglutide arm with weight losses (i.e. Changes in body weight differed according to participants' baseline characteristics (Table S4). At week 120, 5% or higher weight loss from baseline was observed in 48.2% of participants (95 of 197) in the semaglutide arm and in 22.6% (21 of 93) in the placebo arm. Post hoc analyses explored changes in body weight from baseline to week 120 and in a variety of participant subgroups (from baseline to week 68 and week 120, and from week 68 to week 120), and the proportion of participants with 5% or higher weight loss from baseline at week 120. Semaglutide 2.4 mg has shown clinically meaningful bodyweight reductions in obesity both in the primarily white population of the STEP 1‐5 and 8 trials, as well as in the east Asian participants of the STEP 6 trial.Lose Weight Shorts Workout And Shapewear Solutions Can You Get Smooth Kickin Keto Gummies From A Pharmacy Or Walmart Glp1s Without Insurance Glp1 Glp1forweightloss Weightloss 8 Min Standing Upper Body Workout With Light Weights Barbie Ferreira Weight Loss Her Journey And Tips Affordable Weight Loss Medication Without Insurance